Cargando…

A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer

BACKGROUND: Epithelial growth factor receptor inhibitors (EGFRis) and bevacizumab (BEV) are used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). However, few randomized controlled trials (RCTs) have directly compared their relative efficacy on progression-f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumachev, Alexander, Yan, Marie, Berry, Scott, Ko, Yoo-Joung, Martinez, Maria C. R., Shah, Keya, Chan, Kelvin K. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608731/ https://www.ncbi.nlm.nih.gov/pubmed/26474403 http://dx.doi.org/10.1371/journal.pone.0140187

Ejemplares similares

A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
por: Chan, Kelvin, et al.
Publicado: (2014)

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023)

Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma
por: Kapoor, Shailendra
Publicado: (2012)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
por: Pudipeddi, Aviv, et al.
Publicado: (2022)

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
por: Braun, M S, et al.
Publicado: (2003)

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting
por: Riedl, Jakob Michael, et al.
Publicado: (2017)

The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials
por: Segelov, E, et al.
Publicado: (2014)

Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2004)

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
por: Ridouane, Yassine, et al.
Publicado: (2017)

Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives
por: Motta, Rodrigo, et al.
Publicado: (2021)

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
por: Feliu, J, et al.
Publicado: (2004)

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
por: Feng, Maple Ye, et al.
Publicado: (2022)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
por: Goel, Gaurav, et al.
Publicado: (2015)

The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients
por: Tampellini, M, et al.
Publicado: (2006)

Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer
por: Wu, Dong-Mei, et al.
Publicado: (2017)

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
por: Yin, Yong-Mei, et al.
Publicado: (2010)

Levetiracetam as a First-line Agent for Neonatal Seizure
por: Mandal, Anirban, et al.
Publicado: (2017)

Advancements in the Treatment of Psoriasis: Role of Biologic Agents
por: Rich, Sheldon J., et al.
Publicado: (2004)

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US
por: Vachhani, Pankit, et al.
Publicado: (2022)

Drug-induced liver injury
por: Kumachev, Alexander, et al.
Publicado: (2021)

Hyperferritinemia
por: Kumachev, Alexander, et al.
Publicado: (2021)

Hyperferritinémie
por: Kumachev, Alexander, et al.
Publicado: (2021)

Atteinte hépatique médicamenteuse
por: Kumachev, Alexander, et al.
Publicado: (2021)

Neuroleptic malignant syndrome
por: Tan, Carolyn Michelle, et al.
Publicado: (2023)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020)

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
por: Rao, S, et al.
Publicado: (2004)

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
por: Kim, Bum Jun, et al.
Publicado: (2017)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

A First Attempt to Bring Computational Biology into Advanced High School Biology Classrooms
por: Gallagher, Suzanne Renick, et al.
Publicado: (2011)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
por: Arciero, Vanessa, et al.
Publicado: (2022)

Science or Fiction: Use of Nesiritide as a First-Line Agent?
por: Noviasky, John A, et al.
Publicado: (2003)

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
por: Potocki, Paweł Michał, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mf6mrf2p89s7raf6ofjc6ekup5